Takeda and Protagonist’s Mimrylo accredited for polycythemia vera

Adam Feuerstein is a senior author and biotech columnist, reporting on the crossroads of drug improvement, enterprise, Wall Avenue, and biotechnology. He’s additionally a co-host of the weekly biotech podcast The Readout Loud and writer of the publication Adam’s Biotech Scorecard. You may attain Adam on Sign at stataf.54.

The Meals and Drug Administration on Friday accredited a brand new remedy for a uncommon and slow-growing most cancers that causes an overproduction of pink blood cells. 

The drug, referred to as rusfertide, was developed by the biotech firm Protagonist Therapeutics. It will likely be offered by Takeda, the Japanese pharma firm, underneath the model identify Mimrylo. 

Administered by way of a weekly injection, Mimrylo was cleared to deal with polycythemia vera, a continual blood most cancers by which overproduction of pink blood cells thickens a affected person’s blood, leading to larger threat for life-threatening coronary heart assaults, strokes, and blood clots.